Antiulcer acylated 2-hydroxy-3-phenyl-1,3-di:amino-propane cpds. - prepd. e.g. by reacting the corresp non-acylated di:amine with reactive carboxylic acid deriv

Acylated diaminopropane derivs. of formula (I) and their acid addition salts are new: In (I) R1 is 1-20C alkyl, 2-7C alkenyl, 1,3-pentadien-1-yl, 3-7C cycloalkyl or 4-8C cycloalkylmethyl (both opt. substd. by CH3), 5-7C cycloalkenyl or 6-8C cycloalkenylmethyl (both opt. substd. by CH3), adamantyl, adamantylmethyl, benzyl or phenethyl (both opt. 3,4-dimethoxy substd.), phenyl substd. by 2 CH3O's, 3,4-methylenedioxy, 3,4-ethylenedioxy, 3,4-ethylenedioxy, 2-F, 4-F, or by 2-CF3, or R1 is 2-, 3- or 4-pyridyl, or furyl. R2=H, 1-3C alkyl or methoxyethyl. R3 and R4 = H, halo, 1-3C alkyl or alkoxy. The following cpds. are excluded: (a) R1=3,4-dimethoxy 2-F-, or 2-CF3-phenyl or 2-furyl; R2=CH3; R3=H and R4=4-Cl; (b) R1=3,4-dimethoxyphenyl; R2=CH3 and R3+R4 = 3,4-dimethoxy). The cpd. are made e.g. by reacting the corresp. unacylated diamine with a reactive deriv. of R1COOH. (I) are useful for treating ulcers and have no effects on gastric secretion or the CNS. The usual adult dose is 150-450 mg (orally) per day. The cpd. N-acetyl-N2-methyl-N2-(4-chlorophenyl)-2-hydroxy-1,3-diaminopropa- ne has 7-day oral LD50 in mice of 2.26g/kg.